U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07701954) titled 'Single Ascending and Multiple Ascending Dose Study of LCA-0061' on June 25.
Brief Summary: This is a Phase 1combined single ascending dose (SAD)/multiple ascending dose (MAD) randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of LCA-0061in participants with atopic conditions (SAD) and participants with peanut allergy (MAD).
Study Start Date: June 26
Study Type: INTERVENTIONAL
Condition:
Atopic Disease
Peanut Allergies
Intervention:
DRUG: LCA-0061
LCA-0061 is an antibody-based therapeut...